Agilent Technologies Inc. stock (US00846U1016): earnings miss and cautious outlook keep sentiment subdued

Agilent Technologies Inc. recently reported weaker-than-expected quarterly results and trimmed its full-year outlook, while the stock lags the broader market. What is weighing on the life science tools specialist, and how does the core business generate its cash flows?

Agilent Technologies Inc. shares have been under pressure after the life science tools company reported quarterly results that came in below Wall Street expectations and lowered its full-year forecast for fiscal 2024, according to a press release published on May 29, 2024 and follow-up coverage from major financial media on May 30, 2024.Agilent investor relations as of 05/29/2024 and Reuters as of 05/30/2024 reported that softer demand from pharma and chemical customers weighed on orders and margins.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Agilent Technologies
• Sector/industry: Life science tools and analytical instruments
• Headquarters/country: Santa Clara, United States
• Core markets: Pharmaceutical, biotechnology, chemical, diagnostics and academic laboratories worldwide
• Key revenue drivers: Analytical instruments, consumables, software and lab services
• Home exchange/listing venue: New York Stock Exchange (ticker: A)
• Trading currency: US dollar (USD)

Agilent Technologies Inc.: core business model

Agilent Technologies develops and sells laboratory instruments, consumables and software that help scientists analyze chemical and biological samples. The company’s portfolio includes chromatography systems, mass spectrometers, spectroscopy tools and automated sample preparation platforms that are widely used in pharmaceutical development and quality control.

Alongside hardware, Agilent generates recurring revenue from consumables such as columns, reagents and standards, as well as from instrument service contracts and software licenses. This mix of one-time equipment sales and ongoing consumable and service income is designed to smooth revenue over economic cycles, even when customers delay larger capital expenditures.

A further pillar is diagnostics and genomics, where Agilent provides reagents, instruments and workflow solutions for molecular pathology and genomic research. The company supplies clinical labs with products used in cancer diagnostics and supports biopharma customers with quality control tools for biologic drugs, according to product descriptions and business overviews updated on the corporate website in 2024.Agilent company information as of 2024

Main revenue and product drivers for Agilent Technologies Inc.

Agilent reports results across three main segments: Life Sciences and Applied Markets, Agilent CrossLab and Diagnostics and Genomics, as outlined in its fiscal 2023 Form 10-K filed on December 20, 2023.Agilent Form 10-K as of 12/20/2023 Life Sciences and Applied Markets focuses on instruments such as liquid chromatography and mass spectrometry systems sold to pharmaceutical, chemical and environmental customers.

Agilent CrossLab emphasizes services and consumables, including instrument maintenance, training and multi-vendor support. This segment is an important contributor to recurring cash flows because customers often sign multi?year service agreements, helping the company offset volatility in equipment orders during periods of weaker capital spending.

The Diagnostics and Genomics segment delivers reagents, instruments and companion diagnostic solutions used by clinical labs and research institutions. Demand here is linked to trends in oncology testing, genetic analysis and precision medicine, which can support growth over the long term even as individual funding cycles fluctuate.

In the second quarter of fiscal 2024, Agilent reported revenue of around 1.57 billion USD, a slight year-on-year decline, while adjusted earnings per share came in below consensus forecasts, according to the company’s May 29, 2024 earnings release.Agilent investor relations as of 05/29/2024 Management cited continued softness in demand from pharma and chemical customers and noted that some clients remained cautious in placing new orders.

Alongside the weaker quarter, Agilent lowered its full?year fiscal 2024 revenue and earnings guidance, pointing to a slower recovery in key end markets than previously anticipated, as summarized by Reuters as of 05/30/2024. The more conservative outlook contributed to a negative share price reaction in the days following the announcement.

Despite the near?term headwinds, Agilent continues to invest in new products and solutions. In early 2025, the company highlighted expanded offerings in biopharma analytics and cell analysis tools designed to support complex biologics and cell therapy workflows, according to product communication on the corporate website updated in 2025.Agilent newsroom as of 2025 These areas are seen as important growth drivers as pharmaceutical companies increase their spending on biologic drugs and advanced therapies.

Why Agilent Technologies Inc. matters for US investors

For US investors, Agilent represents one of the established players in the life science tools industry listed on the New York Stock Exchange. The company’s instruments and consumables are embedded in drug discovery, clinical diagnostics and chemical quality control workflows, so its performance is closely linked to research and development spending and regulatory trends in the United States.

Agilent generates a significant portion of its revenue from the Americas, and management has repeatedly pointed to resilient service and consumables demand from US pharmaceutical and biotechnology customers, according to commentary in earnings materials released throughout fiscal 2023 and fiscal 2024.Agilent investor relations as of 11/20/2023 This exposure makes the stock sensitive to shifts in US research budgets, capital spending cycles and broader healthcare policy developments.

From a portfolio point of view, the stock is often grouped with other US?listed life science tools names, and its share price can react to sector?wide sentiment as well as company?specific news. For example, when Agilent adjusted its outlook in May 2024, several peers in the analytical instruments space also faced questions about the timing of a demand recovery, according to sector commentary in financial media reports published at the end of May 2024.Bloomberg as of 05/30/2024

Conclusion

Agilent Technologies Inc. is navigating a period of subdued demand in several of its end markets, which has led to an earnings miss and a more cautious outlook for fiscal 2024. At the same time, the company continues to benefit from a large installed base of instruments, recurring service and consumables revenue and exposure to long?term trends in pharmaceutical research and diagnostics. For US investors following the life science tools sector, the stock’s performance is likely to hinge on signs of a recovery in capital spending and on Agilent’s ability to translate its innovation pipeline into sustained growth, without this article providing any form of investment recommendation.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.